

## Abstract & poster highlighting positive clinical results for ColoSTAT® Poster Presentation at ASCO Annual Meeting

### Highlights

- ✓ **The prospective, cross-sectional, multi-centre study evaluated the clinical performance of ColoSTAT® for the detection of biomarkers associated with colorectal cancer, and demonstrated a sensitivity of 81% and 91% specificity, compared to colonoscopy.**

Transformative cancer diagnostics technology company Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) is pleased to announce that the abstract detailing the main results from the clinical trial for ColoSTAT®, its simple blood test for the detection of colorectal cancer (CRC), was published as part of the 2023 ASCO (American Society of Clinical Oncology) Annual Meeting.

The poster presentation associated with the abstract (attached to this announcement) was presented by Dr. Trevor Lockett, as part of the session taking place on 5 June 2023, 8am-11am (US CDT). (See ASX announcement 6 April 2023).

The multi-centre clinical study detailed in the abstract was designed to evaluate the performance of ColoSTAT® in detecting CRC compared to colonoscopy. The study involved two cohorts: those recently diagnosed with CRC using colonoscopy and proceeding to surgery or neoadjuvant treatment, and those with no CRC history scheduled for colonoscopy.

The clinical trial successfully achieved its primary endpoint, with ColoSTAT® demonstrating a sensitivity of 81% and specificity of 91% in detecting CRC. Furthermore, the study's exploratory endpoint found that ColoSTAT® demonstrated consistent sensitivity across different stages of the disease.

The abstract is available on the Rhythm Biosciences website at: [https://rhythmbio.com/publications\\_and\\_posters](https://rhythmbio.com/publications_and_posters)

Globally an estimated 2 million people are diagnosed with CRC each year, and almost 1 million lives were lost to the disease in 2020. It is predicted that the global number of CRC cases will reach 3.2 million in the next 20 years. The challenge with CRC globally has been low participation in screening programs and the increasing incidence rates, particularly among the younger people. It has been shown that 11% of people diagnosed with CRC are below the age of 50, posing a tremendous public health challenge, premature death and increased healthcare costs.<sup>1</sup>

**Rhythm Chief Commercial Officer Ms. Elena Deak commented:** "Our presentation at ASCO has given us the opportunity to inform the medical community about ColoSTAT and its simple methodology for the detection of CRC. We are committed to improving the screening participation rate of Colorectal Cancer, with our simple blood test ColoSTAT®." "

- ENDS -

1. <https://rhythmbio.com/Colorectal-Cancer~219>

#### Rhythm Biosciences Ltd

ACN 619 459 335  
ASX: RHY

[www.rhythmbio.com](http://www.rhythmbio.com)

#### Australian Registered Address

Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

T +61 3 8256 2880  
E [info@rhythmbio.com](mailto:info@rhythmbio.com)

#### Directors

Otto Buttula  
Trevor Lockett  
Rachel David  
Louis Panaccio  
Sue MacLeman

Executive Chairman  
Executive Director  
Non-Executive Director  
Non-Executive Director  
Non-Executive Director

## Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via [investor@rhythmbio.com](mailto:investor@rhythmbio.com) or on +61 3 8256 2880:

<b>Mr Otto Buttula</b> Executive Chairman	<b>Ms Elena Deak</b> Chief Commercial Officer	<b>Mr Paul Smith</b> CFO & Company Secretary
----------------------------------------------	--------------------------------------------------	-------------------------------------------------

### About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and Twitter.

### About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.